MaxCyte
the expert platform enabling non viral cell engineering ats a | MaxCyte
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
15 of 21
Similar slides by MaxCyte
See diffirences between slides (animation)
Results
November 2023
the expert platform enabling non viral cell engineering ats a | MaxCyte
Investor Presentation
October 2023
the expert platform enabling non viral cell engineering ats a | MaxCyte
Investor Presentation
August 2023
the expert platform enabling non viral cell engineering ats a | MaxCyte
Investor Presentation
May 2023
the expert platform enabling non viral cell engineering ats a | MaxCyte
Related slides by other companies
Affirm
Results
February 2025
platform portfolio and funding mix affirm | Affirm
AbCellera
Investor Conference
January 2024
continued focus on high value programs and strategic partnerships with our differentiated technology position in liquidity we have a long cash runway for focused investment execution completion of engine over the next years we will continue to invest in the final stage of our engine including construction commissioning of our manufacturing facility our portfolio of partnered in we anticipate partnership deals from our cell engager platform our partnership strategy is to select high value not deal volume our portfolio of internal we expect to enter clinical development in in we expect additional first in class development candidates from our ion channel platform | AbCellera
Affirm
Results
May 2023
platform portfolio and funding mix | Affirm
D-Wave
SPAC
February 2022
wave at a glance | D-Wave
Other recent decks by MaxCyte
See all presentations (8 decks)
Results
November 2023
Investor Presentation
October 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights